CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Syndax Pharmaceuticals, Inc. (SNDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Syndax Pharmaceuticals, Inc. (SNDX)

Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Syndax Pharmaceuticals (SNDX) is a ~$2.1B market cap clinical-stage pharma with 270 employees, best known for its menin inhibitor revumenib, now in Phase 3 for colorectal cancer. The company carries ~$213M net debt, only ~7.8 months of cash runway, and posted a $285M net loss in 2025 against $172M in revenue, implying heavy near-term financing risk.
The catalyst path
  • 2026-12-01 (est.)Phase 2 · SNDX-5613imp 7/10
  • 2026-12-30 (est.)Phase 2 · Revumenibimp 7/10
  • 2027-06-15 (est.)Phase 2 · entinostatimp 7/10
Pipeline
AssetPhaseIndication
cobicistatPhase 2Acute Myeloid Leukemia
entinostatPhase 2Non-Small Cell Lung Cancer
Aromatase Inhibitor (AI) TherapyPhase 2ER+ Breast Cancer
RevumenibPhase 3Colorectal Cancer
Intensive Chemotherapy RegimenPhase 3Acute Myeloid Leukemias
AxatilimabPhase 2Chronic Graft-versus-host-disease
SNDX-5613Phase 2Acute Myeloid Leukemia
ASTX727Phase 2Acute Myeloid Leukemia
Price & technical context
3-month
-55.4%
6-month
-56.3%
12-month
-47.8%
52-wk range
$8.56–$25.15
vs 50-day MA
-38.7%
vs 200-day MA
-55.1%
Realized vol
60.3%
Max drawdown
-66.0%

Daily closes through 2026-11-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SNDX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.